Anxiety and mood (대한불안의학회지)

Korean Academy of Anxiety Disorders (대한불안의학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative Effectiveness of Adjunctive Aripiprazole versus Bupropion Uses to Selective Serotonin Reuptake Inhibitor on the Specific Symptom of Depression : A post-hoc, Multi-Center, Open-Label, Randomized Study

세로토닌 재흡수 억제제에 대한 아리피프라졸 및 부프로피온 부가요법의 우울증 세부증상에 대한 효과 비교 : 다기관, 개방표지, 무작위 연구

  • Lee, Ga-Won (Department of Psychiatry, College of Medicine, Yeungnam University) ;
  • Lee, Kwang-Hun (Department of Psychiatry, Dongguk University Gyeongju Hospital) ;
  • Park, Young-Woo (Department of Neuropsychiatry, Daegu Fatima Hospital) ;
  • Lee, Jong-hun (Department of Psychiatry, College of Medicine, Daegu Catholic University) ;
  • Koo, Bon-Hoon (Department of Psychiatry, College of Medicine, Yeungnam University) ;
  • Lee, Seung-Jae (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Sung, Hyung-Mo (Department of Psychiatry, College of Medicine, CHA University, CHA Gumi Medical Center) ;
  • Cheon, Eun-Jin (Department of Psychiatry, College of Medicine, Yeungnam University)
  • 이가원 (영남대학교 의과대학 정신건강의학교실) ;
  • 이광헌 (동국대학교 경주병원 정신건강의학과) ;
  • 박영우 (대구파티마병원 정신건강의학과) ;
  • 이종훈 (대구가톨릭대학교 의과대학 정신건강의학교실) ;
  • 구본훈 (영남대학교 의과대학 정신건강의학교실) ;
  • 이승재 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 성형모 (CHA의과학대학교 구미차병원 정신건강의학교실) ;
  • 천은진 (영남대학교 의과대학 정신건강의학교실)
  • Received : 2017.05.30
  • Accepted : 2017.08.23
  • Published : 2017.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The purpose of this study was to examine the effects of adjunctive aripiprazole versus bupropion on specific symptoms of depression. Methods : Data were from 6-week, randomized, prospective, open-label multi-center study in 103 patients with major depressive disorders. Participants were randomized to receive aripiprazole (2.5-10 mg/day) or bupropion (150-300 mg/day) for 6 weeks. Change in four subscales of the 17-item Hamilton Depression Rating Scale (HAM-D17) that capture core depression symptoms was determined, and change in individual HAM-D17 items was also assessed. Changes in three composite subscales-anxiety, insomnia, and drive were also examined. Results : Within-group change in the four core subscales was large [effect size (ES)=1.30-1.47] and it was similar to that in the HAM-D17 total score. Differences between aripiprazole and bupropion were significant for each of the four core subscales and the HAM-D17 total score favored aripiprazole (p<0.001). On three composite scales, both treatments caused substantial changes in anxiety (within-group ES=1.10 (aripiprazole) vs. 1.00 (bupropion)], insomnia (ES=0.75 vs 0.50), and drive (ES=1.17 vs 1.15). Conclusion : This results suggested that both aripiprazole and bupropion adjunctive therapies with selective serotonin reuptake inhibitors resulted in significant and clinically meaningful changes in core symptom subscales for depression.

우울증은 높은 유병률을 가지며 심각하고 만성화 될 수 있는 질병이다. 환자가 증상 없이 기능적 회복이 되어 일상을 영위하기 위해 임상가는 단독요법 이상의 치료 전략이 필요하다. 본 연구에서 SSRI와 aripiprazole 또는 bupropion 부가 요법은 우울증의 증상 호전을 보였다. SSRI와 aripiprazole 부가 요법은 우울증의 전반적 점수의 호전뿐 아니라 세부척도의 핵심 증상에서 bupropion 병합 요법에 비해 더 의미 있는 변화를 보였다. 또한 두 약제 모두 핵심 우울증상이라 할 수 있는 개별증상(우울한 기분, 일과 활동, 정신적 불안)에서 가장 큰 변화를 보였다

Keywords

References

  1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105. https://doi.org/10.1001/jama.289.23.3095
  2. Association AP. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157:1-45. https://doi.org/10.1176/ajp.157.1.1
  3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. The Lancet 1997;349:1498-1504. https://doi.org/10.1016/S0140-6736(96)07492-2
  4. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457-494. https://doi.org/10.1016/S0193-953X(02)00107-7
  5. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40. https://doi.org/10.1176/appi.ajp.163.1.28
  6. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142. https://doi.org/10.1016/S0197-2456(03)00112-0
  7. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. The Canadian Journal of Psychiatry 2000;45:476-481. https://doi.org/10.1177/070674370004500509
  8. Nelson JC. The use of antipsychotic drugs in the treatment of depression. Treating Resistant Depression 1987:131-146.
  9. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013;13:851-870. https://doi.org/10.1586/14737175.2013.811901
  10. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015;76:e487-e498.
  11. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006;59:203-210. https://doi.org/10.1016/j.biopsych.2005.06.027
  12. Evans KR, Sills T, DeBrota DJ, Gelwicks S, Engelhardt N, Santor D. An item response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies. J Psychiatr Res 2004;38:275-284. https://doi.org/10.1016/j.jpsychires.2003.11.003
  13. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton depression rating scale measure? J Psychiatr Res 1993;27:259-273. https://doi.org/10.1016/0022-3956(93)90037-3
  14. Bech P, Gram L, Dein E, Jacobsen O, Vitger J, Bolwig T. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-170. https://doi.org/10.1111/j.1600-0447.1975.tb00002.x
  15. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115. https://doi.org/10.1055/s-2007-1017335
  16. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659. https://doi.org/10.1016/S0006-3223(03)00231-2
  17. Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol 2017;37: 193-199. https://doi.org/10.1097/JCP.0000000000000663
  18. Cohen J. Statistical power analysis for the behavioral sciences Lawrence Earlbaum Associates. Hillsdale, NJ 1988:20-26.
  19. Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010;120:133-140. https://doi.org/10.1016/j.jad.2009.06.026
  20. Nelson JC, Portera L, Leon AC. Assessment of outcome in depression. Journal of Psychopharmacology 2006;20:47-53.
  21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. https://doi.org/10.1136/jnnp.23.1.56
  22. Yi JS, Bae SO, Ahn YM, Park DB, Noh KS, Shin HK, et al. Validity and reliability of the Korean version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc 2005;44: 456-465.
  23. Nasr S, Wendt B, Popli A, Crayton J. Comparing outcomes of adjunctive treatment in depression: Aripiprazole versus Bupropion. J Affect Disord 2014;162:50-54. https://doi.org/10.1016/j.jad.2014.03.019
  24. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D 3 receptors. Eur J Pharmacol 2008;597:27-33. https://doi.org/10.1016/j.ejphar.2008.09.008
  25. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-1531. https://doi.org/10.1046/j.1471-4159.2001.00154.x
  26. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166. https://doi.org/10.4088/PCC.v06n0403
  27. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, Mc-Quade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009;14:197-206. https://doi.org/10.1017/S1092852900020216